Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Timetable
Suzhou Basecare Medical Corp

Suzhou Basecare Medical Corp is an innovative platform of genetic testing solutions for assisted reproduction in China. Its PGT-A kit, which screens for aneuploidy, a chromosomal disorder frequently associated with implantation failure in in vitro fertilization, or IVF, in embryos prior to implantation, is the first and only third-generation IVF genetic test kit which has been approved by the NMPA.

The NMPA registration of its PGT-A kit, in February 2020, as a Class III "innovative medical device," marked the birth of a regulated third-generation IVF market in China in which it is, to date, the only approved kit maker.

The Group is developing two other pre-implantation genetic testing, or PGT, products, namely, PGT-M and PGT-SR kits, which, together with its PGT-A kit, would form a complete test kit lineup to occupy the PGT field. It is expected to obtain NMPA registration approval for these kits in 2022 and 2024, respectively.

In addition to its self-developed products, the Group also distributes DA8600, the only NGS sequencer approved by the NMPA for PGT, on which its test kits are designed to run, and a number of other test kits.

The Group sold a significant portion of products directly to hospitals and reproductive clinics. To a lesser extent, it also sold its genetic test kits to distributors, who in turn sell its products to hospitals and reproductive clinics.

MarketHong Kong (Main Board)
Business NatureHealth Care
Board Lot500
Registrar & Transfer OfficeComputershare Hong Kong Investor Services
No. of Offer Shares66.67m H shares
No. of International Offer Shares60.00m H shares
No. of HK Offer Shares6.67m H shares
Offer Price$26.36 - $27.36
Nominal ValueRMB 1.00 each
Stock Code2170
Sole SponsorCLSA Capital Markets Limited
Joint Global CoordinatorsCLSA Limited, Citigroup Global Markets Asia Limited, China International Capital Corporation Hong Kong Securities Limited
Joint BookrunnersCLSA Limited, Citigroup Global Markets Asia Limited, Citigroup Global Markets Limited, China International Capital Corporation Hong Kong Securities Limited, Haitong International Securities Company Limited, CMB International Capital Limited, ICBC International Capital Limited, SPDB International Capital Limited
Joint Lead ManagersCLSA Limited, Citigroup Global Markets Asia Limited, Citigroup Global Markets Limited, China International Capital Corporation Hong Kong Securities Limited, Haitong International Securities Company Limited, CMB International Capital Limited, ICBC International Capital Limited, SPDB International Capital Limited, Futu Securities International (Hong Kong) Limited
Application PeriodJan 27 (Wed) - Noon, Feb 1 (Mon)
Price Determination DateOn or Before 5pm, Feb 1 (Mon)
Result Announcement DateOn or Before Feb 5 (Fri)
Dispatch of Shares and Refund ChequesOn or Before Feb 5 (Fri)
Dealings in Shares commence onFeb 8, 2021. (Mon)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
ExecutiveLIANG Bo (Chairman), KONG Lingyin, RUI Maoshe
Non-ExecutiveXU Wenbo, ZHANG Jiecheng, WANG Weipeng
Independent Non-ExecutiveKANG Xixiong, HUANG Taosheng, YU Kwok Kuen Harry
Director LIANG Bo34.25%
Zhongcheng Fangyuan Phase II5.70%
Hillhouse HK5.11%
(Year ended Dec 31)
2020 *20192018
Gross Profit20,47726,2538,137
Pre-Taxed Profit(852,724)(530,570)(157,005)
Attributable Profit for the period(851,384)(531,336)(154,877)
* For the nine months ended September 30, 2020.
Attributable Loss (not more than)880m
Offer Price$26.36 - $27.36
Capitalization (H Shares)$1,953m - $2,027m
Unaudited pro forma adj NAV / share$7.58 - $7.82
Assuming the offer price being at the mid-point of $26.86, the net proceeds raised would be HK$1,684.7m, of which:
* $505.4m (30.0%) will be allocated to the Core Product, the PGT-A kit ;
* $336.9m (20.0%) to be used for the clinical trial, registration filing and commercialization of PGT-M kit ;
* $505.4m (30.0%) to be allocated to the development, clinical trials and registration filings of other products;
* $168.5m (10.0%) to be used for improving research and; development capabilities and enhancing technologies; and
* the balance of $168.5m (10.0%) as additional working capital.
Code Name Nominal Change %Change
08622HUAKANG BIOMEDunchange0.0940.0000.000%
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
  Quote data is at least 15-min delayed,last updated: 13/04/2021 17:59
IPO Calculator
Subscription --
Result Announcement --      Listing --
Offer Price︰--
Currency :
Listing Price
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.003% and Stock Exchange trading fee of 0.005% (i.e. 1.008% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.